(Q36653838)

15 August 2017

1 reference

title

British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006). (English)

1 reference

15 August 2017

main subject

anti-retroviral agent

0 references

author name string

B Gazzard

1

1 reference

15 August 2017

A J Bernard

2

1 reference

15 August 2017

M Boffito

3

1 reference

15 August 2017

D Churchill

4

1 reference

15 August 2017

S Edwards

5

1 reference

15 August 2017

N Fisher

6

1 reference

15 August 2017

A M Geretti

7

1 reference

15 August 2017

M Johnson

8

1 reference

15 August 2017

C Leen

9

1 reference

15 August 2017

B Peters

10

1 reference

15 August 2017

A Pozniak

11

1 reference

15 August 2017

J Ross

12

1 reference

15 August 2017

J Walsh

13

1 reference

15 August 2017

E Wilkins

14

1 reference

15 August 2017

M Youle

15

1 reference

15 August 2017

Writing Committee, British HIV Association

16

1 reference

15 August 2017

publication date

1 November 2006

1 reference

15 August 2017

1 reference

15 August 2017

volume

7

1 reference

15 August 2017

issue

8

1 reference

15 August 2017

page(s)

487-503

1 reference

Multidisciplinary HIV adherence intervention: a randomized study.

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00424.X

Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00424.X

Changing the paradigm for HIV testing--the end of exceptionalism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00424.X

Clinical efficacy of early initiation of HAART in patients with asymptomatic HIV infection and CD4 cell count > 350 × 106/l

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00424.X

Clinical and immunogenetic correlates of abacavir hypersensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00424.X

Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00424.X

Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00424.X

The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00424.X

Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00424.X

Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00424.X

Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00424.X

The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00424.X

Randomized, controlled study of the effects of a short course of prednisone on the incidence of rash associated with nevirapine in patients infected with HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00424.X

Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00424.X

Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00424.X

SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00424.X

Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00424.X

Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00424.X

Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00424.X

Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00424.X

Findings from the first national clinical audit of treatment for people with HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00424.X

Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00424.X

Abacavir once or twice daily combined with once-daily lamivudine and efavirenz for the treatment of antiretroviral-naive HIV-infected adults: results of the Ziagen Once Daily in Antiretroviral Combination Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00424.X

Abacavir and lamivudine fixed-dose combination tablet once daily compared with abacavir and lamivudine twice daily in HIV-infected patients over 48 weeks (ESS30008, SEAL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00424.X

Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00424.X

Minor changes in calculated creatinine clearance and anion-gap are associated with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00424.X

Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00424.X

Early virologic failure in HIV-1 infected subjects on didanosine/tenofovir/efavirenz: 12-week results from a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00424.X

Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naive patients: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00424.X

The use of plasma HIV RNA as a study endpoint in efficacy trials of antiretroviral drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00424.X

Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00424.X

Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00424.X

Enhanced replicative capacity and pathogenicity of HIV-1 isolated from individuals infected with drug-resistant virus and declining CD4+ T-cell counts

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00424.X

Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00424.X

Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00424.X

Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00424.X

Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00424.X

Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: a randomized pilot study (E-184V study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00424.X

Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00424.X

HIV-1 subtypes: epidemiology and significance for HIV management

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00424.X

Renal safety of tenofovir disoproxil fumarate in HIV-1 treatment-experienced patients with adverse events related to prior NRTI use: data from a prospective, observational, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00424.X

The cost of HIV medication adherence support interventions: Results of a cross-site evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00424.X

Genetic evolution of HIV in patients remaining on a stable HAART regimen despite insufficient viral suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00424.X

10.1111/J.1468-1293.2006.00424.X

21 January 2018

Identifiers

DOI

1 reference

release_x2zd6wpibbfpzgrpvqu5bqblbq

15 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/x2zd6wpibbfpzgrpvqu5bqblbq

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference